Ignite Creation Date:
2024-05-05 @ 11:03 PM
Last Modification Date:
2024-10-26 @ 10:27 AM
Study NCT ID:
NCT01242111
Status:
TERMINATED
Last Update Posted:
2015-09-30
First Post:
2010-10-28
Brief Title:
A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA Morquio A Syndrome
Sponsor:
BioMarin Pharmaceutical
Organization:
BioMarin Pharmaceutical
Study Overview
Official Title:
A Multicenter Multinational Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA Morquio A Syndrome
Status:
TERMINATED
Status Verified Date:
2015-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This multicenter open-label extension study is designed to assess long-term efficacy and safety of 20 milligrams mgkilogramkgweek of BMN 110 in patients diagnosed with Mucopolysaccharidosis IVA MPS IVA Patients with MPS IVA who enrolled in a prior BioMarin sponsored clinical study of BMN 110 NCT00884949 Study Identification Number MOR-002 were eligible to enroll in this study except patients who enrolled in NCT01275066 Study Identification Number MOR-004
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None